Low Sodium Oxybate

ApprovedSmall molecule

SStanford University

Low Sodium Oxybate is one of 37 small molecule programs targeting Idiopathic Hypersomnia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Idiopathic HypersomniaActive, not recruiting

Cluster HeadacheActive, not recruiting

Idiopathic HypersomniaApproved

Active, not recruiting

Cluster HeadachePhase 2

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Cluster Headache

#DrugCompanyPhaseTrials

Medrol

Pfizer

Approved

1 2

Topamax

WWim Janssens

Approved

1 3

Emgality

Eli Lilly

Phase 3

3 4

Ajovy

Teva

Phase 3

3 5

Vyepti

Lundbeck

Phase 3

2 6

Xyrem

Jazz Pharmaceuticals

Phase 3

1 7

Rituxan

Roche

Phase 3

—8

Botox

RRevance Therapeutics, Inc.

Phase 3

3 9

Calan

VVal Adams

Phase 3

1 10

Sumatriptan Succinate

GSK

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalNot yet recruiting

Idiopathic Hypersomnia

NCT07077278

Q2 2028

Phase 2Not yet recruiting

Cluster Headache

NCT06950281

Clinical

Trials by Indication[1]

Idiopathic Hypersomnia2 trials

Low Sodium Oxybate in Patients With Idiopathic Hypersomnia

Recruiting·MMayo Clinic·Phase 4·NCT05837091·30 enrolled

Effect of Low Sodium Oxybate (LXB) on Autonomic Symptom Burden in Idiopathic Hypersomnia Patients With Postural Tachycardia Syndrome

Not yet recruiting·SStanford University·Phase 4·NCT07077278·25 enrolled

Cluster headache1 trial

Efficacy, Safety and Tolerability of Low Sodium Oxybate for Nocturnal Cluster Headache Attacks

Not yet recruiting·LLeiden University Medical Center·Phase 2·NCT06950281·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Low Sodium Oxybate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Low Sodium Oxybate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Low Sodium Oxybate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: SStanford University

Low Sodium Oxybate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2028

Trials by Indication[1]

Idiopathic Hypersomnia2 trials

Cluster headache1 trial

References

Drug Info

Quick Facts

Related News